Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

NCT07360132 | Not Yet Recruiting Phase 3

• 1 other identifier: HB0025-C-0302
• Study Type: interventional
• Target: 480
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a randomized, controlled, double-blind, multi-center phase III registration clinical trial, aiming to observe, compare and evaluate the efficacy and safety of HB0025 combined with paclitaxel + carboplatin compared with pembrolizumab combined with paclitaxel + carboplatin as the first-line treatment for locally advanced or metastatic squamous NSCLC. The study subjects are patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) who have not received systemic anti-tumor treatment before. The study will use the PFS evaluated by BICR as the primary endpoint, and plan to enroll approximately 480 subjects, with the proportion of locally advanced subjects not exceeding 10%. The subjects were fully informed and signed the informed consent form. If they met the inclusion criteria but did not meet the exclusion criteria, they were randomly assigned in a 1:1 ratio to receive HB0025 combined with chemotherapy Paclitaxel plus Platinum (experimental group) or pembrolizumab combined with chemotherapy Paclitaxel plus Platinum (control group). Both were administered once every 3 weeks (Q3W). After 4 cycles of treatment, Enter HB0025 or pembrolizumab monotherapy maintenance treatment (Q3W) until the investigator determines that there is no longer any clinical benefit (based on the RECIST v1.1 imaging assessment and comprehensive clinical symptom assessment by the investigator), intolerable toxicity occurs, 24 months of study treatment is completed, or other treatment termination criteria in the protocol are met. Whichever occurs first shall prevail.

Conditions

Squamous Non-small Cell Lung Cancer

Keywords

HB0025; sq-NSCLC; Fiest Line treatment

Outcome Measures

Primary Outcomes (1)

• Progression-free survival (PFS)

  PFS is defined as the time from the date of randomization till the first documentation of disease progression (per RECIST v1.1 criteria) assessed by the investigator or death due to any cause (whichever occurs first)

  Up to approximately 24 Months

Secondary Outcomes (12)

• Overall Survival (OS)

  Up to 24 Months

• Objective Response Rate (ORR)

  Up to 24 Months

• Disease control rate (DCR)

  Up to 24 Months

• Duration of response (DOR)

  Up to 24 Months

• Time to Progression(TTP)

  Up to 24 Months

Other Outcomes (1)

• PD-L1 expression

  Approximately 16 months.

Study Arms (2)

HB0025

EXPERIMENTAL

HB0025 combined with Carboplatin Injection plus Paclitaxel Injection, IV, every 3 weeks(Q3W)

Drug: Carboplatin Injection; Drug: Paclitaxel Injection

Pembrolizumab

ACTIVE COMPARATOR

pembrolizumab combined with Carboplatin Injection plus Paclitaxel Injection, IV every 3 weeks (Q3w)

Drug: Carboplatin Injection; Drug: Paclitaxel Injection

Interventions

Carboplatin Injection DRUG

10mL:100mL, Q3W

HB0025; Pembrolizumab

Paclitaxel Injection DRUG

5ml:30mg, Q3W

HB0025; Pembrolizumab

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Able to fully understand and voluntarily sign the informed consent form, and willing and able to comply with the clinical study procedures and follow-up visits.
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-1.
• Expected survival ≥ 12 weeks.
• Histologically or cytologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) (confirmed per the 9th Edition of the TNM Staging System for Lung Cancer by the Union for International Cancer Control \[UICC\] and the American Joint Committee on Cancer \[AJCC\]) that is inoperable for radical resection and ineligible for radical concurrent/sequential chemoradiotherapy or immunotherapy as consolidation treatment.
• Note: For subjects with locally advanced (Stage IIIB/IIIC) NSCLC who are inoperable for radical resection and ineligible for radical concurrent/sequential chemoradiotherapy or immunotherapy as consolidation treatment, an assessment by relevant specialist physicians and provision of written documentation are required for confirmation.
• \. No previous systemic anti-tumor treatment for locally advanced or metastatic squamous NSCLC \[For subjects who have received adjuvant/neoadjuvant therapy for the purpose of cure for non-metastatic disease or radical concurrent/sequential chemoradiotherapy for locally advanced disease (including subjects receiving PD-1/L1 inhibitors), If disease progression occurs more than 12 months after the end of the last treatment, one is eligible to participate in this study.
• \. Subjects must provide tumor tissue samples (archived or freshly obtained) collected at or after the diagnosis of locally advanced or metastatic tumor for central laboratory testing of PD-L1 expression.
• Note:The following samples are not accepted: fine-needle aspiration samples (without intact tissue structure, only cell suspensions or smears), brush cytology samples, cell smears from centrifuged pleural effusion drainage, bronchoalveolar lavage fluid samples, and bone lesions without soft tissue components or decalcified bone tumor samples.
• \. No sensitive EGFR mutations or ALK gene rearrangements. Prior tissue-based test reports for EGFR and ALK status must be provided. If the test reports do not meet the study requirements or are unavailable, tumor tissue samples must be provided for assessment of EGFR and ALK status (tested by a local laboratory recognized by the study site or the central laboratory) before enrollment.
• Note: For subjects with squamous NSCLC (excluding mixed-type NSCLC, e.g., adenosquamous carcinoma) who have a smoking history or are current smokers, if the prior EGFR and ALK status is unknown, testing for these markers is not required before enrollment, and they will be deemed negative.
• \. At least one measurable (non-brain metastatic) lesion per RECIST v1.1 criteria, which is suitable for repeated and accurate measurement. Tumor lesions previously treated with radiotherapy or other local therapies cannot be designated as target lesions, unless:
• The lesion is the only measurable lesion, and the investigator can provide imaging evidence (before and after local treatment) confirming clear disease progression of the lesion after local treatment;
• The lesion used for fresh tissue biopsy is the only measurable lesion. 10. Confirmed adequate organ function, as evidenced by meeting the following laboratory parameters: 1) Hematology (no receipt of blood component transfusion or hematopoietic growth factor support within 14 days before screening tests):
• Absolute Neutrophil Count (ANC) ≥ 1.5 × 10⁹/L;
• Platelet Count (PLT) ≥ 100 × 10⁹/L;

You may not qualify if:

• \. Female and male subjects of childbearing potential must agree to use effective contraceptive measures from the screening period until 90 days after the last dose of study treatment. Discussion with the investigator is required to determine whether contraception can be discontinued after this period. Female subjects must not be breastfeeding. Female subjects of childbearing potential must have a negative serum pregnancy test result within 7 days before randomization.
• Histologically confirmed presence of any small cell carcinoma, neuroendocrine carcinoma, or sarcoma components \[mixed-type NSCLC (e.g., adenosquamous carcinoma) is permitted for enrollment\].
• Known presence of driver gene alterations with approved first-line therapeutic options, such as sensitive EGFR mutations, ALK fusion, ROS1 fusion, BRAF V600 mutation, NTRK fusion, MET exon 14 skipping mutation, or RET fusion.
• History of a second primary malignancy within 3 years before Randomization (enrollment is permitted for other malignancies cured by local treatment, e.g., carcinoma in situ of the cervix, localized cutaneous squamous cell carcinoma, basal cell carcinoma, ductal carcinoma in situ of the breast, \< T1 urothelial carcinoma, and papillary microcarcinoma of the thyroid).
• Symptomatic central nervous system (CNS) metastasis; or diameter of brain metastases ≤ 1.5 cm, or receipt of CNS radiotherapy within 2 weeks before randomization; or anticipated need for CNS radiotherapy during the first treatment cycle after randomization. Subjects with asymptomatic CNS metastasis or symptomatically stable CNS metastasis (≥ 2 weeks before randomization) are permitted for enrollment only if all the following criteria are met:
• No increase in lesion size or new lesions after treatment; ② No history of intracranial hemorrhage;
• Discontinuation of corticosteroid therapy \> 3 days before randomization;
• Diameter of brain metastases \< 1.5 cm.
• Prior receipt of immunotherapy, including immune checkpoint inhibitors (e.g., anti-PD-1/L1/L2, anti-CTLA-4 agents), immune checkpoint agonists (e.g., ICOS, CD40, GITR, OX40, CD137 agents), or cellular immunotherapy, or any treatment targeting the tumor immune mechanism. Additionally, for subjects who received PD-(L)1 inhibitors in the neoadjuvant/adjuvant setting or as consolidation therapy after definitive chemoradiotherapy, enrollment may be permitted (with sponsor approval) if disease progression occurs \> 12 months after the last dose of prior treatment.
• Prior receipt of systemic anti-angiogenic therapy, including but not limited to bevacizumab and its biosimilars, Endostar, small-molecule TKIs, and ramucirumab.
• Prior antineoplastic treatment or concomitant medication use (washout period calculated from the end of the last treatment):
• <!-- -->
• Concurrent enrollment in another clinical trial, unless it is an observational, non-interventional clinical trial or the follow-up phase of an interventional clinical trial (defined as an interval of ≥ 4 weeks between the last dose of the previous study drug and randomization in this study);
• Receipt of chest radiotherapy with \> 30 Gy within 180 days before randomization; non-chest radiotherapy with \> 30 Gy within 4 weeks before randomization; local palliative radiotherapy with ≤ 30 Gy for non-target lesions within 2 weeks before randomization;
• Use of Chinese herbal medicines (with antineoplastic indications) within 1 week before randomization; receipt of non-specific immunomodulatory therapy (e.g., interleukin, interferon, thymosin, tumor necrosis factor, excluding IL-11 for thrombocytopenia treatment) within 2 weeks before randomization;

Sponsors & Collaborators

• Shanghai Huaota Biopharmaceutical Co., Ltd.: lead

Study Sites (1)

The East Hospital Affiliated to Tongji University

Shanghai, Shanghai Municipality, 200120, China

Location

MeSH Terms

Interventions

Carboplatin; Paclitaxel

Intervention Hierarchy (Ancestors)

Coordination Complexes; Organic Chemicals; Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Diterpenes; Terpenes

Central Study Contacts

Caicun Zhou

CONTACT

+86 021-58822171; CAICUNZHOUDR@TONGJI.EDU.CN

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: It is planned to enroll approximately 480 subjects, and they will be randomly divided into groups at a ratio of 1:1. The treatment is administered once every 3 weeks (Q3W). After 4 cycles of treatment, patients will proceed to receive maintenance therapy with HB0025 or pembrolizumab alone (also Q3W). Experimental group: HB0025 combined with chemotherapy Paclitaxel plus Platinum; Control group: pembrolizumab combined with chemotherapy Paclitaxel plus Platinum.

Study Record Dates

• First Submitted: January 13, 2026
• First Posted: January 22, 2026
• Study Start: January 15, 2026
• Primary Completion (Estimated): April 10, 2028
• Study Completion (Estimated): August 10, 2028
• Last Updated: January 22, 2026

Record last verified: 2026-01

Locations

CN (1)